Base de dados : MEDLINE
Pesquisa : colestase [Palavras]
Referências encontradas : 23416 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2342 ir para página                         

  1 / 23416 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778443
[Au] Autor:Krawczyk M; Liebe R; Wasilewicz M; Wunsch E; Raszeja-Wyszomirska J; Milkiewicz P
[Ad] Endereço:Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
[Ti] Título:Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch.
[So] Source:Liver Int;37(5):743-747, 2017 May.
[Is] ISSN:1478-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: The amelioration of refractory cholestatic pruritus after plasmapheresis has been reported in single patients. Here, we analyse the efficacy of plasmapheresis in a cohort of patients with primary biliary cholangitis (PBC). METHODS: Seventeen consecutive patients with PBC (age range 39-85 years, 16 females, 9 with cirrhosis) and refractory pruritus underwent 129 plasmapheresis procedures during 40 admissions. Pruritus was quantified by the 10-point numeric rating scale (NRS) before and after plasmapheresis, as well as ~30 and ~90 days later. RESULTS: The mean pruritus before plasmapheresis did not differ between patients with and without cirrhosis (P>.05). Cirrhotics presented, however, with significantly higher serum alanine aminotransferase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and bilirubin before plasmapheresis. Plasmapheresis decreased itching to NRS≤5 in all but five admissions: Mean pruritus decreased from 8.3±1.4 to 3.1±2.2 (P<.0001) in the entire cohort. It also led to a significant decrease in serum ALT, ALP, AST, GGT (all P<.001) and bilirubin (P=.002). Antipruritic effect persisted throughout the 90-days follow-up (P<.0001). The amelioration of pruritus was not affected by the presence of cirrhosis. CONCLUSIONS: Plasmapheresis is a promising method for reducing intractable itch in a significant proportion of PBC patients regardless of liver fibrosis. Long-lasting improvement of symptoms requires repeated procedures.
[Mh] Termos MeSH primário: Colestase/complicações
Cirrose Hepática Biliar/complicações
Plasmaferese
Prurido/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Fosfatase Alcalina/sangue
Aspartato Aminotransferases/sangue
Bilirrubina/sangue
Feminino
Seres Humanos
Fígado/patologia
Masculino
Meia-Idade
Polônia
Prurido/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.6.1.1 (Aspartate Aminotransferases); EC 3.1.3.1 (Alkaline Phosphatase); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/liv.13281


  2 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419378
[Au] Autor:Chappell LC; Chambers J; Thornton JG; Williamson C
[Ad] Endereço:Women's Health Academic Centre, King's College London, London, UK lucy.chappell@kcl.ac.uk.
[Ti] Título:Does ursodeoxycholic acid improve perinatal outcomes in women with intrahepatic cholestasis of pregnancy?
[So] Source:BMJ;360:k104, 2018 02 01.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Colagogos e Coleréticos/efeitos adversos
Colestase Intra-Hepática/tratamento farmacológico
Feto/efeitos dos fármacos
Complicações na Gravidez/tratamento farmacológico
Ácido Ursodesoxicólico/efeitos adversos
[Mh] Termos MeSH secundário: Colagogos e Coleréticos/administração & dosagem
Colagogos e Coleréticos/uso terapêutico
Colestase Intra-Hepática/epidemiologia
Feminino
Seres Humanos
Gravidez
Complicações na Gravidez/epidemiologia
Resultado da Gravidez/epidemiologia
Ácido Ursodesoxicólico/administração & dosagem
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k104


  3 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775690
[Au] Autor:Kennedy LL; Meng F; Venter JK; Zhou T; Karstens WA; Hargrove LA; Wu N; Kyritsi K; Greene J; Invernizzi P; Bernuzzi F; Glaser SS; Francis HL; Alpini G
[Ad] Endereço:Research, Central Texas Veterans Health Care System, Temple, TX, USA.
[Ti] Título:Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice.
[So] Source:Lab Invest;96(12):1256-1267, 2016 12.
[Is] ISSN:1530-0307
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21 mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression. In vitro, immortalized murine biliary cell lines (IMCLs) and human hepatic stellate cell line (hHSC) were treated with either miR-21 inhibitor or control before analyzing proliferation, apoptosis, and fibrotic responses. In vivo, the levels of miR-21 were increased in total liver and cholangiocytes after BDL, and loss of miR-21 decreased the amount of BDL-induced biliary proliferation and intrahepatic biliary mass. In addition, loss of miR-21 decreased BDL-induced HSC activation, collagen deposition, and expression of the fibrotic markers transforming growth factor-ß1 and α-smooth muscle actin. In vitro, IMCL and hHSCs treated with miR-21 inhibitor displayed decreased proliferation and expression of fibrotic markers and enhanced apoptosis when compared with control treated cells. Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis. During cholestatic injury, miR-21 is increased and leads to increased biliary proliferation and hepatic fibrosis. Local modulation of miR-21 may be a therapeutic option for patients with cholestasis.
[Mh] Termos MeSH primário: Ductos Biliares Intra-Hepáticos/metabolismo
Colestase Intra-Hepática/metabolismo
Modelos Animais de Doenças
Células Estreladas do Fígado/metabolismo
MicroRNAs/metabolismo
Regulação para Cima
[Mh] Termos MeSH secundário: Animais
Apoptose
Ductos Biliares Intra-Hepáticos/patologia
Biomarcadores/metabolismo
Linhagem Celular
Proliferação Celular
Células Cultivadas
Colestase Intra-Hepática/patologia
Colestase Intra-Hepática/fisiopatologia
Progressão da Doença
Regulação da Expressão Gênica
Células Estreladas do Fígado/patologia
Seres Humanos
Hiperplasia
Cirrose Hepática/etiologia
Masculino
Camundongos
Camundongos Knockout
MicroRNAs/antagonistas & inibidores
MicroRNAs/biossíntese
Interferência de RNA
Proteína Smad7/genética
Proteína Smad7/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Biomarkers); 0 (MIRN21 microRNA, human); 0 (MIRN21 microRNA, mouse); 0 (MicroRNAs); 0 (Smad7 Protein)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/labinvest.2016.112


  4 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390323
[Au] Autor:Xiang D; He J; Wang H; Xiong F; Cheng H; Ai J; Shan R; Wan R; Zhang L; Shi J
[Ad] Endereço:Department of General Surgery, The First Affiliated Hospital of Nanchang University.
[Ti] Título:Liver transplantation for decompensated liver cirrhosis caused by progressive familial intrahepatic cholestasis type 3: A case report.
[So] Source:Medicine (Baltimore);96(50):e9158, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Progressive familial intrahepatic cholestasis (PFIC) type 3, characterized by high gamma glutamyl transferase (GGT), is an autosomal recessive genetic disease. It often occurs in patients' first years of age. However, high GGT type PFIC is still rare. PATIENT CONCERNS: The present study reports a case of liver transplantation for decompensated liver cirrhosis caused by PFIC type 3. An 18-year-old male presented with a history of abdominal distension and jaundice for 2 months. He had abdominal tenderness but no rebounding pain. Moreover, his dullness was felt over the liver and the spleen was palpable 8 cm below the ribs. DIAGNOSES: Computed tomography and magnetic resonance cholangiopancreato graphy of the upper abdomen revealed cirrhosis, portal hypertension, collateral circulation formation, large spleen, and ascites. Blood biochemistry showed high alanine transaminase, aspartate transaminase, and GGT. The diagnosis of decompensated liver cirrhosis caused by PFIC-3 was finally confirmed by plasma gene detecting. INTERVENTIONS: The patient received an open surgery named allogeneic liver transplantation after successful matching of immune types between the recipient and donor. Peritoneal puncture and catheter drainage under B-ultrasound was performed when an encapsulated effusion between the liver and stomach arose. OUTCOMES: The patient was discharged without specific discomfort and was almost free of fluid accumulation 51 days after the surgery. At the 6-month follow-up, he had no discomfort and the blood routine, liver functions showed no abnormalities. LESSONS: We found a new mutant fragment of ABCB4 gene in the process of diagnosis. Liver transplantation remains the most definitive treatment for PFIC. Current medical therapies and surgical interventions such as biliary diversion have potentially created a synergistic outcome.
[Mh] Termos MeSH primário: Subfamília B de Transportador de Cassetes de Ligação de ATP/deficiência
Colestase Intra-Hepática/complicações
Cirrose Hepática/etiologia
Cirrose Hepática/cirurgia
Transplante de Fígado
[Mh] Termos MeSH secundário: Adolescente
Seres Humanos
Cirrose Hepática/diagnóstico por imagem
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP Binding Cassette Transporter, Sub-Family B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009158


  5 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241862
[Au] Autor:Nicosia L; Cannataci C; Cortis K; Mauri G
[Ad] Endereço:Postgraduate School of Radiology, Università degli Studi di Milano, Milan, Italy.
[Ti] Título:Can a multidisciplinary approach improve the care of patients with benign biliary strictures?
[So] Source:Gastrointest Endosc;87(1):322-323, 2018 01.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Colestase
[Mh] Termos MeSH secundário: Constrição Patológica
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  6 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384912
[Au] Autor:Han B; Sheng Y; Wang L; Feng H; Hou X; Li Y
[Ad] Endereço:Centre for Reproductive Medicine.
[Ti] Título:Intrahepatic cholestasis of pregnancy or azithromycin-induced intrahepatic cholestasis: A case report.
[So] Source:Medicine (Baltimore);96(52):e9346, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Azithromycin-induced liver injury has been rarely reported in adult individuals, let alone in a pregnant woman. Here, we describe the clinical features and outcomes of azithromycin-induced liver injury in a pregnant woman. PATIENT CONCERNS: A 30-year-old pregnant woman presented with generalized pruritus and elevated serum bile acid level (123.6 µmol/L) on day 4 of azithromycin administration. A diagnosis of intrahepatic cholestasis of pregnancy was made, and cesarean section was performed immediately. Interestingly, the alanine aminotransferase level (ALT) reached 211.2 U/L on day 9 after azithromycin administration. DIAGNOSIS: Therefore, drug-induced intrahepatic cholestasis was considered. INTERVENTIONS: (1) Azithromycin withdrawal after the patient hospitalized. (2) Termination of pregnancy by cesarean section was performed inmmediately to protect the fetus. (3) Silymarin capsules and bifendate are used to protect the liver after liver enzymes elevation was discovered. OUTCOMES: The liver enzymes recovered within 4 weeks without any symptoms after treatment with silymarin capsules and bifendate, which helps reduce ALT level and protects the liver from further injury. LESSIONS: A pregnant woman developed azithromycin-induced intrahepatic cholestasis. Physicians should be aware of this side effect of azithromycin, which is widely prescribed.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Azitromicina/efeitos adversos
Colestase Intra-Hepática/induzido quimicamente
Colestase Intra-Hepática/diagnóstico
Complicações na Gravidez/induzido quimicamente
Complicações na Gravidez/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Cesárea
Colestase Intra-Hepática/terapia
Feminino
Seres Humanos
Gravidez
Complicações na Gravidez/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 83905-01-5 (Azithromycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009346


  7 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770549
[Au] Autor:Zhang L; Yang Z; Trottier J; Barbier O; Wang L
[Ad] Endereço:Department of Physiology and Neurobiology and Institute for Systems Genomics, University of Connecticut, Storrs, CT.
[Ti] Título:Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay.
[So] Source:Hepatology;65(2):604-615, 2017 Feb.
[Is] ISSN:1527-3350
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bile acids (BAs) play critical physiological functions in cholesterol homeostasis, and deregulation of BA metabolism causes cholestatic liver injury. The long noncoding RNA maternally expressed gene 3 (MEG3) was recently shown as a potential tumor suppressor; however, its basic hepatic function remains elusive. Using RNA pull-down with biotin-labeled sense or anti-sense MEG 3RNA followed by mass spectrometry, we identified RNA-binding protein polypyrimidine tract-binding protein 1 (PTBP1) as a MEG3 interacting protein and validated their interaction by RNA immunoprecipitation (RIP). Bioinformatics analysis revealed putative binding sites for PTBP1 within the coding region (CDS) of small heterodimer partner (SHP), a key repressor of BA biosynthesis. Forced expression of MEG3 in hepatocellular carcinoma cells guided and facilitated PTBP1 binding to the Shp CDS, resulting in Shp mRNA decay. Transient overexpression of MEG3 RNA in vivo in mouse liver caused rapid Shp mRNA degradation and cholestatic liver injury, which was accompanied by the disruption of BA homeostasis, elevation of liver enzymes, as well as dysregulation of BA synthetic enzymes and metabolic genes. Interestingly, RNA sequencing coupled with quantitative PCR (qPCR) revealed a drastic induction of MEG3 RNA in Shp liver. SHP inhibited MEG3 gene transcription by repressing cAMP response element-binding protein (CREB) transactivation of the MEG3 promoter. In addition, the expression of MEG3 and PTBP1 was activated in human fibrotic and cirrhotic livers. CONCLUSION: MEG3 causes cholestasis by serving as a guide RNA scaffold to recruit PTBP1 to destabilize Shp mRNA. SHP in turn represses CREB-mediated activation of MEG3 expression in a feedback-regulatory fashion. (Hepatology 2017;65:604-615).
[Mh] Termos MeSH primário: Colestase/metabolismo
Ribonucleoproteínas Nucleares Heterogêneas/genética
Fígado/lesões
Proteína de Ligação a Regiões Ricas em Polipirimidinas/genética
Estabilidade de RNA/genética
RNA Longo não Codificante/genética
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Células Cultivadas
Colestase/patologia
Modelos Animais de Doenças
Regulação para Baixo
Células Hep G2
Hepatócitos/citologia
Hepatócitos/metabolismo
Seres Humanos
Fígado/patologia
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Regiões Promotoras Genéticas
Distribuição Aleatória
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heterogeneous-Nuclear Ribonucleoproteins); 0 (MEG3 non-coding RNA, mouse); 0 (Ptbp1 protein, mouse); 0 (RNA, Long Noncoding); 139076-35-0 (Polypyrimidine Tract-Binding Protein)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE
[do] DOI:10.1002/hep.28882


  8 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310413
[Au] Autor:Yang MJ; Kim JH; Hwang JC; Yoo BM; Kim SS; Lim SG; Won JH
[Ad] Endereço:Department of Gastroenterology.
[Ti] Título:Usefulness of combined percutaneous-endoscopic rendezvous techniques after failed therapeutic endoscopic retrograde cholangiography in the era of endoscopic ultrasound guided rendezvous.
[So] Source:Medicine (Baltimore);96(48):e8991, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The rendezvous approach is a salvage technique after failure of endoscopic retrograde cholangiography (ERC). In certain circumstances, percutaneous-endoscopic rendezvous (PE-RV) is preferred, and endoscopic ultrasound-guided rendezvous (EUS-RV) is difficult to perform. We aimed to evaluate PE-RV outcomes, describe the PE-RV techniques, and identify potential indications for PE-RV over EUS-RV.Retrospective analysis was conducted of a prospectively designed ERC database between January 2005 and December 2016 at a tertiary referral center including cases where PE-RV was used as a salvage procedure after ERC failure.During the study period, PE-RV was performed in 42 cases after failed therapeutic ERC; 15 had a surgically altered enteric anatomy. The technical success rate of PE-RV was 92.9% (39/42), with a therapeutic success rate of 88.1% (37/42). Potential indications for PE-RV over EUS-RV were identified in 23 cases, and either PE-RV or EUS-RV could have effectively been used in 19 cases. Endoscopic bile duct access was successfully achieved with PE-RV in 39 cases with accessible biliary orifice using one of PE-RV cannulation techniques (classic, n = 11; parallel, n = 19; and adjunctive maneuvers, n = 9).PE-RV uses a unique technology and has clinical indications that distinguish it from EUS-RV. Therefore, PE-RV can still be considered a useful salvage technique for the treatment of biliary obstruction after ERC failure.
[Mh] Termos MeSH primário: Colangiopancreatografia Retrógrada Endoscópica
Colestase/diagnóstico por imagem
Colestase/cirurgia
Endossonografia
[Mh] Termos MeSH secundário: Ductos Biliares/diagnóstico por imagem
Ductos Biliares/cirurgia
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Melhoria de Qualidade
Estudos Retrospectivos
Terapia de Salvação
Resultado do Tratamento
Ultrassonografia de Intervenção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008991


  9 / 23416 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310368
[Au] Autor:Hong JB; Kang DH; Nam HS; Choi CW; Kim HW; Park SB; Kim SJ; Choi WH
[Ad] Endereço:Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
[Ti] Título:Endoscopic reintervention for stent malfunction after stent-in-stent deployment for malignant hilar obstruction.
[So] Source:Medicine (Baltimore);96(48):e8867, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endoscopic bilateral stenting has been increasingly performed for advanced hilar obstruction. As disease progresses, stent malfunction eventually occurs. However, endoscopic reintervention is difficult in these patients. We aimed to evaluate a suitable reintervention procedure for stent malfunction after stent-in-stent (SIS) deployment for malignant hilar obstruction.Among 52 patients with bilateral stenting performed using the SIS method between September 2009 and June 2016, 20 patients with stent malfunction were enrolled in this study. Reintervention was performed endoscopically or percutaneously. Technical and functional success rates were evaluated retrospectively.Technical and functional success rates of endoscopic reintervention were 83% (10/12) and 80% (8/10), respectively. Endoscopic bilateral and unilateral reintervention success rates were 75% (6/8) and 100% (4/4), respectively. For bilateral reintervention, either plastic or plastic and metal stents were used.Endoscopic reintervention could be considered for in-stent malfunction if patients are in fair condition after SIS placement for malignant hilar obstruction. Decisions regarding whether to use bilateral or unilateral drainage and the type of stent to use should depend on the conditions of the disease and the patient.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/cirurgia
Colestase Intra-Hepática/cirurgia
Endoscopia/métodos
Stents
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Neoplasias dos Ductos Biliares/diagnóstico por imagem
Colestase Intra-Hepática/diagnóstico por imagem
Progressão da Doença
Falha de Equipamento
Feminino
Seres Humanos
Masculino
Meia-Idade
Reoperação
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008867


  10 / 23416 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29205025
[Au] Autor:Siiki A; Laukkarinen J
[Ti] Título:Can we prevent post-ERCP pancreatitis?
[So] Source:Duodecim;133(3):267-74, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Endoscopic retrograde cholangiopancreatography (ERCP) is the primary method for treating cholestasis and biliary tract gallstones. Although noninvasive imaging has replaced ERCP in diagnostics, ERCP remains the mainstay in collecting diagnostic specimens from the biliary tract. ERCP carries a risk of post-ERCP pancreatitis, which can vary from mild to life-threatening. Difficult cannulation is the most important risk factor for pancreatitis. Careful patient selection and adequate endoscopy training are the foundation of safe ERCP practice. Current evidence supports the routine use of prophylactic rectal NSAID in all patients to prevent post-ERCP pancreatitis.
[Mh] Termos MeSH primário: Colangiopancreatografia Retrógrada Endoscópica/efeitos adversos
Colelitíase/diagnóstico por imagem
Colestase/diagnóstico por imagem
Pancreatite/etiologia
Pancreatite/prevenção & controle
[Mh] Termos MeSH secundário: Anti-Inflamatórios não Esteroides/administração & dosagem
Cateterismo/efeitos adversos
Seres Humanos
Seleção de Pacientes
Reto
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE



página 1 de 2342 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde